Management of children with isolated testicular leukemia

S. D. Smith, R. C. Trueworthy, P. M. Klopovich, T. S. Vats, W. Snodgrass

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Since 1975, nine children with testicular leukemia were treated at the University of Kansas Medical Center on a standard protocol. Six patients presented with overt testicular leukemia and three patients had microscopic testicular leukemia detected on a biopsy done after 3 years of continuous complete remission. All patients had an M1 bone marrow at the time of testicular relapse and one patient had a concomitant central nervous system (CNS) relapse. Therapy consisted of testicular irradiation. CNS chemoprophylaxis, and systemic reinduction chemotherapy. Systemic maintenance therapy after the testicular relapse consisted of 6-mercaptopurine and methotrexate with vincristine/prednisone pulses administered in the same basic dose and schedule as the patient's original maintenance regimen. These nine patients had a mean duration of first remission of 33 months and a mean duration of second remission of 45+ months. Four patients have relapsed (two bone marrow, one CNS, one CNS + bone marrow), but five patients remain in their second complete remission for 33+ to 94+ months from the time of testicular relapse. These results demonstrate that, in some children, testicular leukemia represents a site of temporary drug resistance and long-term second remissions can be obtained (once local disease is controlled) by using the initial maintenance chemotherapy regimen.

Original languageEnglish (US)
Pages (from-to)2854-2858
Number of pages5
JournalCancer
Volume54
Issue number12
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Leukemia
Central Nervous System
Recurrence
Bone Marrow
Maintenance Chemotherapy
6-Mercaptopurine
Chemoprevention
Vincristine
Prednisone
Drug Resistance
Methotrexate
Appointments and Schedules
Maintenance
Biopsy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, S. D., Trueworthy, R. C., Klopovich, P. M., Vats, T. S., & Snodgrass, W. (1984). Management of children with isolated testicular leukemia. Cancer, 54(12), 2854-2858. https://doi.org/10.1002/1097-0142(19841215)54:12<2854::AID-CNCR2820541207>3.0.CO;2-J

Management of children with isolated testicular leukemia. / Smith, S. D.; Trueworthy, R. C.; Klopovich, P. M.; Vats, T. S.; Snodgrass, W.

In: Cancer, Vol. 54, No. 12, 1984, p. 2854-2858.

Research output: Contribution to journalArticle

Smith, SD, Trueworthy, RC, Klopovich, PM, Vats, TS & Snodgrass, W 1984, 'Management of children with isolated testicular leukemia', Cancer, vol. 54, no. 12, pp. 2854-2858. https://doi.org/10.1002/1097-0142(19841215)54:12<2854::AID-CNCR2820541207>3.0.CO;2-J
Smith, S. D. ; Trueworthy, R. C. ; Klopovich, P. M. ; Vats, T. S. ; Snodgrass, W. / Management of children with isolated testicular leukemia. In: Cancer. 1984 ; Vol. 54, No. 12. pp. 2854-2858.
@article{05b968cd22bb457a9cf3f7e068309b39,
title = "Management of children with isolated testicular leukemia",
abstract = "Since 1975, nine children with testicular leukemia were treated at the University of Kansas Medical Center on a standard protocol. Six patients presented with overt testicular leukemia and three patients had microscopic testicular leukemia detected on a biopsy done after 3 years of continuous complete remission. All patients had an M1 bone marrow at the time of testicular relapse and one patient had a concomitant central nervous system (CNS) relapse. Therapy consisted of testicular irradiation. CNS chemoprophylaxis, and systemic reinduction chemotherapy. Systemic maintenance therapy after the testicular relapse consisted of 6-mercaptopurine and methotrexate with vincristine/prednisone pulses administered in the same basic dose and schedule as the patient's original maintenance regimen. These nine patients had a mean duration of first remission of 33 months and a mean duration of second remission of 45+ months. Four patients have relapsed (two bone marrow, one CNS, one CNS + bone marrow), but five patients remain in their second complete remission for 33+ to 94+ months from the time of testicular relapse. These results demonstrate that, in some children, testicular leukemia represents a site of temporary drug resistance and long-term second remissions can be obtained (once local disease is controlled) by using the initial maintenance chemotherapy regimen.",
author = "Smith, {S. D.} and Trueworthy, {R. C.} and Klopovich, {P. M.} and Vats, {T. S.} and W. Snodgrass",
year = "1984",
doi = "10.1002/1097-0142(19841215)54:12<2854::AID-CNCR2820541207>3.0.CO;2-J",
language = "English (US)",
volume = "54",
pages = "2854--2858",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Management of children with isolated testicular leukemia

AU - Smith, S. D.

AU - Trueworthy, R. C.

AU - Klopovich, P. M.

AU - Vats, T. S.

AU - Snodgrass, W.

PY - 1984

Y1 - 1984

N2 - Since 1975, nine children with testicular leukemia were treated at the University of Kansas Medical Center on a standard protocol. Six patients presented with overt testicular leukemia and three patients had microscopic testicular leukemia detected on a biopsy done after 3 years of continuous complete remission. All patients had an M1 bone marrow at the time of testicular relapse and one patient had a concomitant central nervous system (CNS) relapse. Therapy consisted of testicular irradiation. CNS chemoprophylaxis, and systemic reinduction chemotherapy. Systemic maintenance therapy after the testicular relapse consisted of 6-mercaptopurine and methotrexate with vincristine/prednisone pulses administered in the same basic dose and schedule as the patient's original maintenance regimen. These nine patients had a mean duration of first remission of 33 months and a mean duration of second remission of 45+ months. Four patients have relapsed (two bone marrow, one CNS, one CNS + bone marrow), but five patients remain in their second complete remission for 33+ to 94+ months from the time of testicular relapse. These results demonstrate that, in some children, testicular leukemia represents a site of temporary drug resistance and long-term second remissions can be obtained (once local disease is controlled) by using the initial maintenance chemotherapy regimen.

AB - Since 1975, nine children with testicular leukemia were treated at the University of Kansas Medical Center on a standard protocol. Six patients presented with overt testicular leukemia and three patients had microscopic testicular leukemia detected on a biopsy done after 3 years of continuous complete remission. All patients had an M1 bone marrow at the time of testicular relapse and one patient had a concomitant central nervous system (CNS) relapse. Therapy consisted of testicular irradiation. CNS chemoprophylaxis, and systemic reinduction chemotherapy. Systemic maintenance therapy after the testicular relapse consisted of 6-mercaptopurine and methotrexate with vincristine/prednisone pulses administered in the same basic dose and schedule as the patient's original maintenance regimen. These nine patients had a mean duration of first remission of 33 months and a mean duration of second remission of 45+ months. Four patients have relapsed (two bone marrow, one CNS, one CNS + bone marrow), but five patients remain in their second complete remission for 33+ to 94+ months from the time of testicular relapse. These results demonstrate that, in some children, testicular leukemia represents a site of temporary drug resistance and long-term second remissions can be obtained (once local disease is controlled) by using the initial maintenance chemotherapy regimen.

UR - http://www.scopus.com/inward/record.url?scp=0021705421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021705421&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19841215)54:12<2854::AID-CNCR2820541207>3.0.CO;2-J

DO - 10.1002/1097-0142(19841215)54:12<2854::AID-CNCR2820541207>3.0.CO;2-J

M3 - Article

C2 - 6498764

AN - SCOPUS:0021705421

VL - 54

SP - 2854

EP - 2858

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -